Table 3 Treatment response to apatinib monotherapy or combination therapy
From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
Monotherapy response (n, %) | Combination therapy response (n, %) | Overall response (n, %) | |
|---|---|---|---|
Complete response (CR) | 0 (0%) | 0 (0%) | 0 (0%) |
Partial response (PR) | 6 (21.43%) | 7 (53.85%) | 13 (31.71%) |
Stable disease (SD) | 17 (60.71%) | 2 (15.38%) | 19 (46.34%) |
Progressive disease (PD) | 5 (17.86%) | 4 (30.77%) | 9 (21.95%) |
Objective response rate (ORR) | 6 (21.43%) | 7 (53.85%) | 13 (31.71%) |
Disease control rate (DCR) | 23 (82.14%) | 9 (69.23%) | 32 (78.05%) |